Table 2. Studies investigating the effects of PM2.5 in cardiovascular homeostasis and function.
This table summarizes in vitro and in vivo studies published to date investigating the physiological effects of PM2.5 in cardiovascular system, which show association between PM2.5 intoxication and CVDs. PM; particulate matter. NIST; National Institutes of Standards and Technology. eNOS; endothelial nitric oxide synthase.
Disease type | Phenotype | Species | Species or cell lines used for investigation | Exp. Type | Treatment method | Treatment dosage & duration | Source of PM2.5 | Ref. |
---|---|---|---|---|---|---|---|---|
Cardiac dysfunction | Cardiac ATP synthesis abnormality | Rat | H9c2 (rat cardiomyocyte cell line) | In vitro | Submerged cell culture | 1–10 μg/cm2 PM2.5 for 24 h | Taiyuan, China | [29] |
Cardiac dysfunction | Functional cardiotoxicities, mitochondrial dysfunction, DNA damage | Rat | Neonatal rat cardiomyocyte (NRCM) | In vitro | Submerged cell culture | 25, 50, 75, 100, 200 and 400 μg/ml for 48 h | Taiyuan, China | [55] |
Cardiac dysfunction | Contractile dysfunction, reduced calcium handling ability | Rat | Sprague Dawley (SD) rat cardiomyocytes | In vitro | Submerged cell culture | 0.25, 0.50, 1.0, and 25 μg/ml for 1h | Diesel exhaust particle (DEP), NIST Standard Reference Matter (SRM) 1650b | [64] |
Cardiac dysfunction | Exacerbates High Glucose-Induced Cardiomyocyte Dysfunction through ROS Generation | Rat | Sprague Dawley (SD) rat cardiomyocytes | In vitro | Submerged cell culture | 0.1 μg/ml for 24h | Diesel exhaust particle (DEP), NIST Standard Reference Matter (SRM) 1650b | [54] |
Cardiac dysfunction | Mitochondria-mediated apoptosis | Human | AC16 | In vitro | Submerged cell culture | 25, 50, and 100 μg/ml for 24h | Beijing, China | [58] |
Cardiac dysfunction | Cardiac ATP synthesis abnormality; functional decrement of myocardium | Rat | Sprague Dawley (SD) rats | In vivo | Intratracheal instillation | summer PM2.5 groups (0.2, 0.6, 1.5 mg/kg, and winter PM2.5 group (0.3, 1.5, 2.7 mg/kg), once every 3 days for 2 months | Taiyuan, China | [29] |
Cardiac dysfunction | Cardiac fibrosis | Mouse | C57BL/6 mice | In vivo | Oropharyngeal aspiration | 3 mg/kg every other day for 4 weeks | Taiyuan, China | [36] |
Cardiac dysfunction | Myocardial Ischemia/Reperfusion Injury Through Farnesoid-X-Receptor-Induced Autophagy | Rat | Sprague Dawley (SD) rats | In vivo | Intratracheal instillation | 6.67 mg/ml for 24 h | Lanzhou, China | [60] |
Cardiac dysfunction | Autophagy; decreased myocardial layers in the heart | Zebrafis h | Zebrafish embryos; wildtype zebrafish (AB strain) and transgenic zebrafish (Tg:zlyz-enhanced green fluorescent protein (EGFP)) | In vivo | Submerged cell culture | 200, 300, 400, 500, 600, and 800 μg/ml for 120 h | Jinan, China | [56] |
Cardiac dysfunction | Fibrosis, myocardial remodeling, inflammatory response, oxidative stress | Rat | Wistar rats | In vivo | Exposure chamber | daily average of between 600–800 μg/m3, 5 days a week, for 4 weeks, or 7 weeks | São Paulo, Brazil | [52] |
Cardiac dysfunction | Fibrosis, myocardial remodeling, inflammatory response, oxidative stress | Mouse | BALB/c mice | In vivo | Intratracheal instillation | 4.0 mg/kg, once per day for 5 consecutive days | China | [49] |
Cardiac dysfunction | Cardiomyopathy confers susceptibility to particulate matter-induced oxidative stress, vagal dominance, arrhythmia, and pulmonary inflammation | Rat | Spontaneously Hypertensive Heart Failure (SHHF) rats | In vivo | 24-port nose-only flow-by inhalation chambers | 580 μg/m3 for 4h | Synthesized by combining metal compounds in molar ratios comparable to those in the historic residual oil fly ash (ROFA) sample collected as a postcontrol fugitive stack emission at a Florida Power and Light plant burning #6 grade residual oil containing 1% sulfur | [67] |
Cardiac dysfunction | Cardiac and mitochondrial dysfunction | Rat | Sprague Dawley (SD) rats | In vivo | Intratracheal instillation | 300 μl of vehicle (5% FBS in PBS) with 300 μg of PM for 24 h | Collected within one mile of an active mountaintop removal mines (MTM) site | [59] |
Cardiac dysfunction | Exacerbation of viral myocarditis | Mouse | BALB/c mice | In vivo | Intratracheal instillation | 10 mg/kg for 7d | Non-industrial district in Shanghai, China | [41] |
Cardiac dysfunction | Exacerbation of viral myocarditis | Mouse | BALB/c mice | In vivo | Intratracheal instillation | 10 mg/kg for 7d | Non-industrial district in Shanghai, China | [42] |
Cardiac dysfunction | Systemic oxidative stress | Mouse | ApoE−/− mice, C57BL/6 mice | In vivo | Intratracheal instillation | 3, 10, or 30 mg/kg for 3d | Shanghai, China | [69] |
Cardiac dysfunction | Inflammation, oxidative stress, hypercoagulation, cardiomyocyte apoptosis | Rat | Wistar rats | In vivo | Intratracheal instillation | 0, 4, 40 mg/kg once every 2d for 3 times | Beijing, China | [53] |
Cardiac dysfunction | Inflammation, imbalance of oxidative stress, the altered Ca2+ channel related proteins and the increased intracellular free Ca2+, heart impairment | Mouse | BALB/c mice | In vivo | Intratracheal instillation | 0.01 mg/μl for 2d | Hebei, China | [46] |
Cardiac dysfunction | Cardiomyopathy, oxidative stress, fibrosis, inflammation, mitochondrial disorder | Mouse | C57BL/6J mice; wild type (Nrf2+/+) and Nrf2 knockout (Nrf2−/−) mice | In vivo | Exposure chamber | 50.1 ± 2.5 μg/m3, flow rate of 65 L/min for 6 h/day, 5 times a week, for 24 weeks | Yuquan Road, Beijing, China | [47] |
Cardiac dysfunction | Cardiac hypertrophy, fibrosis, metabolic alterations | Mouse | C57BL/6J mice | In vivo | Exposure chamber | 100 μg/m3, flow rate 3.5-4.0 L/min, exposed for 28 consecutive days (6 h/day), with 2 days of break every 5 days | Taipei Main Station, Taiwan | [10] |
Cardiac dysfunction | Increased glycemic homeostasis, inflammation, myocarditis, aortic medial thickness | Rat | Sprague Dawley (SD) rats | In vivo | Exposure chamber | PM2.5 at ambient concentration for 24 h/day, 7 days/week, for a total of 16 weeks | Taipei City, Taiwan | [43] |
Cardiac dysfunction | Impaired oxygen metabolism and contractile function | Mouse | Swiss mice | In vivo | Intranasal instillation | 1 mg/kg | Mystic, Connecticut, USA | [91] |
Cardiac dysfunction | Systemic adverse effects, alterations in lung and cardiac gene expression | Mouse | BALB/c mice | In vivo | Intratracheal instillation | 100 μg of PM2.5 in 100 μl of isotonic saline solution on d0, d3, d6 | Milan, Italy | [50] |
Cardiac dysfunction | Systemic and pulmonary inflammation, decreased left ventricular ejection fraction, pulmonary and myocardial fibrosis and oxidative stress | Mouse, human | C57BL/6J mice and AMPKα2−/− mice for in vivo, human bronchial epithelial BEAS-2B cells and rat cardio myoblast H9C2 cells for in vitro | In vivo, in vitro | Intratracheal instillation, Submerged cell culture | 10 mg/kg PM2.5 in 10 μl PBS every other day for 4w in vivo, 24h in vitro | China | [88] |
Vascular dysfunction | Vascular inflammation, decreased viability, migration and angiogenesis | Human | Human umbilical vein endothelial cells (HUVECs), human microvascular endothelial cells (HMEC-1) | In vitro | Submerged cell culture | 0–800 μg/ml for 6h | NIST Standard Reference Matter (SRM) | [77] |
Vascular dysfunction | Autophagy, FHL2 upregulation, IL-6 production, activation of NF-κB pathway | Mouse | Mouse aortic endothelial cells (MAECs) | In vitro | Submerged cell culture | 100 μg/ml for 24 h | Beijing, China | [63] |
Vascular dysfunction | Oxidative stress and reduced the PAI-1 production of endothelial cells | Rat | Rat heart microvessel endothelial (RHMVE) cells | In vitro | Submerged cell culture | 0, 5, 10, and 25 μg/ml for 12h | Saitama, Japan | [78] |
Vascular dysfunction | Vascular remodeling, exacerbated transition from left ventricular failure to right ventricular hypertrophy | Mouse | BALB/c mice | In vivo | Exposure chamber | Local PM2.5 for 10h each day for 3w | Beijing, China | [66] |
Vascular dysfunction | Atherosclerosis progression, activation of circulating leukocytes, platelets and associated inflammatory factors | Mouse | ApoE−/− mice | In vivo | Intratracheal instillation | 30 mg/kg each day for 8w | Shijiazhuang, China | [80] |
Vascular dysfunction | Disseminated intravascular coagulation, inflammatory response, vascular endothelial injury and prothrombotic state | Rat | Sprague Dawley (SD) rats | In vivo | Intratracheal instillation | 0, 1.8, 5.4 and 16.2 mg/kg every 3 days for 30d | Beijing, China | [84] |
Vascular dysfunction | Autophagy, VEGF induction, inflammation | Rat | Sprague Dawley (SD) rats | In vivo | Intratracheal instillation | 1.5 mg/kg every 2d for 3 times | Wuhan, China | [86] |
Vascular dysfunction | Intracraneal atherosclerosis | Rat | Sprague Dawley (SD) rats | In vivo | Exposure chamber | Ambient PM2.5 for 6w or 12w | Beijing, China | [89] |
Vascular dysfunction | Endoplasmic reticulum instability, ANGII-dependent endothelial dysfunction | Rat | Sprague Dawley (SD) rats | In vivo | Intratracheal instillation | 1.5 mg/kg every 2d for 3 times | Wuhan, China | [83] |
Vascular dysfunction | Endothelial dysfunction, decreased endothelium-dependent relaxation and eNOS expression on pulmonary arteries associated with local inflammation | Rat | Wistar rats | In vivo | Exposure chamber | Ambient PM2.5 (approx. 600 μg/m3) for 2w | São Paulo, Brazil | [82] |
Cardiac dysfunction | Heart failure, acute inflammatory response, chronic matrix remodeling, electrical remodeling, epigenetic changes | Mouse | FVB mice | In utero | Exposure chamber | average concentration of 73.61 μg/m3, for 6h/day, 7 days/week | Columbus, Ohio, USA | [51] |
Cardiac dysfunction | Neonatal cardiac dysfunction | Mouse | FVB mice | In utero | Exposure chamber | average concentration of 91.87 μg/m3, for 6h/day, 5 days/week throughout gestation period (20 days) | Columbus, Ohio, USA | [65] |
Cardiac dysfunction | Cardiac dysfunction | Mouse | FVB mice | In utero | Exposure chamber | average concentration of 38.58 μg/m3 for 6 hours/day, 5 days/week for 3 months | Columbus, Ohio, USA | [48] |